We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Patricia Coyle

Patricia K. Coyle MD, FAAN, FANA

Professor and Interim Chair, Department of Neurology; Director, MS Comprehensive Care Center, Stony Brook University Medical Center, Stony Brook, New York

Patricia K. Coyle, MD, FAAN, FANA, is Interim Chair and Professor of Neurology, as well as Director of the Stony Brook Multiple Sclerosis (MS) Comprehensive Care Center. She earned her medical degree and completed her residency in neurology at Johns Hopkins University School of Medicine in Baltimore, MD, where she also completed a fellowship in neuroimmunology and neurovirology. Her areas of expertise include MS, neuroimmunology, and neurologic infectious disease (in particular, Lyme disease).

Dr. Coyle has held multiple leadership positions at the American Board of Psychiatry and Neurology, the American Academy of Neurology, the American Neurological Association, and the National MS Society. She has served as an adviser to the FDA and the Institute of Medicine. Dr. Coyle has received research funding from the NIH and the National MS Society, and is actively engaged in studies to understand and treat these diseases.

Disclosures

Dr. Coyle receives consulting and nonbranded speaker fees from Accordant, Biogen Idec, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Mylan, Novartis, Serono, and TG Therapeutics; research support from Actelion, Alkermes, Corrona LLD, Genentech/Roche, MedDay, NINDS, and Novartis.